Azitra Q1 net loss $3.1M, cash $3.2M; secures up to $20M funding from Alumni Capital

Azitra, Inc.

2025-Q1 EPS reported -$0.23

Net loss $3.1M for Q1 2025 vs $2.9M in Q1 2024; R&D $1.3M, G&A $1.9M.
Cash $3.2M as of March 31, 2025; signed up to $20M purchase agreement with Alumni Capital LP.
Closed two public offerings raising $2.2M.
ATR-12 Phase 1b initial safety data expected 1H 2025; topline data by YE 2025.
ATR-04 Phase 1/2 first patient dosing expected 1H 2025; ASCO poster accepted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.